Feasibility of SARS-CoV-2 Antibody Testing in Remote Outpatient Trials.

ABSTRACT:

Background

During the coronavirus disease 2019 (COVID-19) pandemic, clinical trials necessitated rapid testing to be performed remotely. Dried blood spot (DBS) techniques have enabled remote HIV virologic testing globally, and more recently, antibody testing as well. We evaluated DBS testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody testing in outpatients to assess seropositivity.

Methods

In 2020, we conducted 3 internet-based randomized clinical trials and offered serologic testing via self-collected DBS as a voluntary substudy. COVID-19 diagnosis was based on the Centers for Disease Control and Prevention case definition with epidemiological link to cases. A minority reported polymerase chain reaction (PCR) testing at an outside facility. We

SUBMITTER: Lofgren SM 

PROVIDER: S-EPMC8522439 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature